Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group

Journal of Clinical Oncology

Volumn 14, Issue 7, 1996, Pages 2150-2159

  Zittoun, R ^a   Suciu, S ^a   Mandelli, F ^a   De Witte, T ^a   Thaler, J ^a   Stryckmans, P ^a   Hayat, M ^a   Peetermans, M ^a   Cadiou, M ^a   Solbu, G ^a   Petti, M C ^a   Willemze, R ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL;

EID: 8944234342     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.7.2150     Document Type: Article

References (29)

1. Löwenberg B, Touw IP: Hematopoietic growth factors and their receptors in acute leukemia. Blood 81:281-292, 1993
2. Cannistra SA, DiCarlo J, Groshek P, et al: Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 5:230-238, 1991
3. Aglietta M, De Felice L, Stacchini A, et al: In vivo effect of granulocyte-macrophage colony-stimulating factor on the kinetics of human acute myeloid leukemia cells. Leukemia 5:979-984, 1991
4. Koistinen P, Wang C, Curtis JE, et al: Granulocyte-macrophage colony-stimulating factor and interleukin 3 protect leukemic blast cells from Ara-C toxicity. Leukemia 5:789-795, 1991
5. Lotem J, Sachs L: Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor b1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 80:1750-1757, 1992
6. Bettelheim P, Valent P, Andreef M, et al: Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77:700-711, 1991
7. Büchner T, Hiddeman W, Koenigsmann M, et al: Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78:1190-1197, 1991
8. Bernell P, Kimby E, Hast R: Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: A pilot study. Leukemia 8:1631-1639, 1994
9. Valent P, Sillaber C, Geissler K, et al: Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: Effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts. Med Pediatr Oncol suppl 2:18-22, 1992
10. Ohno R, Tomonaga M, Kobayashi T, et al.: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engt J Med 323:871-877, 1990
11. Ohno R, Naoe T, Kanamaru A, et al: A double-blind controlled study of granulocyte-colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 83:2086-2092, 1994
12. Witz F, Harousseau JL, Cahn JY, et al: GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia. Blood 84:231a, 1994 (suppl 1)
13. Rowe JM, Andersen JP, Mazza JJ, et al.: A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia (AML): A study of the Eastern Cooperative Oncology Group (E1490). Blood 86:457-462, 1995
14. Stone RM, George SL, Berg DT, et al: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332:1671-1677, 1995
15. Dombret H, Chastang C, Fenaux P, et al: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 332:1678-1683, 1995
16. Heil G, Chadid L, Hoelzer D, et al: GM-CSF in a double blind randomized placebo controlled trial in therapy of adults patients with de novo acute myeloid leukemia (AML). Leukemia 9:3-9, 1995
17. Zittoun RA, Mandelli F, Willemze R, et al: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 322:217-223, 1995
18. Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British cooperative group. Ann Intern Med 103:620-625, 1985
19. Buyse M, Staquet M, Sylvester R: Cancer Clinical Trials: Methods and Practice. Oxford, United Kingdom, Oxford University, 1984
20. Gardner MJ, Altman DG (eds): Statistics With Confidence. Belfast, United Kingdom, Br Med J Pub, The University Press, 1989
21. Keating MJ, Smith TL, Kantarjian H, et al.: Cytogenetic pattern in acute myelogenous leukemia: A major reproductible determinant of outcome. Leukemia 2:403-412, 1988
22. Wiley JS, Cebon JS, Jamieson GP, et al: Assessment of proliferative responses to granulocyte-macrophage colony-stimulating (GM-CSF) in acute myeloid leukemia using a fluorescent ligand for the nucleoside transporter. Leukemia 8:181-185, 1994
23. Wiley JS, Cebon JS, Jamieson GP, et al: Cytokine priming of acute myeloid leukemia may produce a pulmonary syndrome when associated with a rapid increase in peripheral blood myeloblasts. Blood 82:3511-3512, 1993
24. Estey E, Thall PF, Kantarjian H, et al: Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macro-phage colony-stimulating factor (GM-CSF) before and during continuous-infusion high dose Ara-C + daunorubicin: Comparison to patients treated without GM-CSF. Blood 79:2246-2255, 1992
25. Archimbaud E, Fenaux P, Reiffers J, et al: Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide and cytarabine for refractory acute myelogenous leukemia. Leukemia 7:372-377, 1993
26. Büchner T, Hiddeman W, Rottman R, et al: Multiple course chemotherapy with or without GM-CSF priming and longterm administration for newly diagnosed AML. Proc Am Soc Clin Oncol 12:985, 1993 (abstr)
27. Estey E, Thall P, Andreef M, et al: Use of granulocyte colonystimulating factor before, during and after Fludarabine plus Cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with Fludarabine plus Cytarabine without granulocyte stimulating factor. J Clin Oncol 12:671-678, 1994
28. Gandhi V, Du M, Kantarjian HM, et al: Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabino-sylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia 8:1463-1468, 1994
29. American Society of Clinical Oncology recommendations for the use of hemopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994